Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Professor Bo Öberg to its Board. Professor Öberg, CEO of Medivir HIV Franchise AB, brings almost 40 years of pharmaceutical industry experience as a senior executive and board member in both biotechnology and pharmaceutical companies.
“We are very pleased that Bo Öberg has accepted our invitation to join the Beactica Board. As we continue to build our portfolio of internal and partnership discovery programmes, Bo’s long experience in R&D strategic planning will be an important addition to the Company” said Dr Per Källblad, CEO of Beactica.
Bo Öberg commented: “I am delighted to join the Board of Beactica, one of the most exciting drug discovery companies to emerge in the last years. Strong scientific foundation and dedication to deliver value has enabled Beactica to build an impressive range of collaborations with some of the top life-science and pharmaceutical companies globally. I look forward to contributing to their continued success.”
Professor Öberg cofounded Medivir AB in 1988 and has held a number of executive and board positions with the company including Chairman of the Board from 1992 to 1996. He is currently CEO of Medivir HIV Franchise AB. Prior to founding Medivir, Bo was Senior Director of Antiviral Therapy R&D at Astra from 1978 to 1988. He has held corporate board positions with a number of companies including Clean Chemical Sweden AB, BioAgri AB, Agrivir AB and Accuro Immunology AB. Bo Öberg became a adjunct professor at the Department of Virology at the Karolinska Institute in 1984. He has served, and continues to serve, on a number of scientific advisory committees. In particular, he is Chair of the Advisory Board of the RAPID Centre and Member of the Advisory Board of the Centre for Infectious Medicine. Bo was Member of the Board of the Swedish Research Council for Medicine, Director of the Board of the International Society for Antiviral Research and Member of the Committee on Biotechnology of the Swedish Board for Technical Development, Member of WHO Advisory Group on Antiviral Chemotherapy and a Member of the Royal Society of Sciences in Uppsala.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. Beactica’s Sprint™ drug discovery platform efficiently integrates surface plasmon resonance (SPR) to accelerate the identification of optimal starting points and development routes for lead discovery. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit www.beactica.com.